CoChat

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Antibody–drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, a novel B7H3-targeting ADC, leverages a tumor microenvironment activable linker-payload platform, coupled with a novel topoisomerase 1 inhibitor via a protease-cleavable linker. Here we report the findings from a large-scale, global, multicenter, phase 1 trial evaluating the safety, pharmacokinetics and preliminary efficacy of YL201 in patients with advanced solid tumors refractory to standard therapies. The trial included a dose-escalation part (phase 1) and a dose-expansion part (phase 1b). A total of 312 patients were enrolled across multiple tumor types, including extensive-stage small cell lung cancer (ES-SCLC), nasopharyngeal carcinoma (NPC), non-small cell lung cancer, esophageal squamous cell carcinoma and other solid tumors. The maximum tolerated dose was determined to be 2.8 mg kg−1, and the recommended expansion dose was selected as 2.0 mg kg−1 and 2.4 mg kg−1 every 3 weeks. The most common grade 3 or higher treatment-related adverse events included neutropenia (31.7%), leukopenia (29.5%) and anemia (25.0%). Only 4 cases of interstitial lung disease (1.3%) and 1 case of infusion reactions (0.3%) were observed. Encouraging anti-tumor activity was observed, particularly in patients with ES-SCLC (objective response rate (ORR), 63.9%), NPC (ORR, 48.6%), lung adenocarcinoma (ORR, 28.6%) and lymphoepithelioma-like carcinoma (ORR, 54.2%). No significant correlation between B7H3 membrane expression and the ORR was found. YL201 demonstrated an acceptable safety profile and a promising efficacy in heavily pretreated patients with advanced solid tumors, particularly in those with ES-SCLC, NPC or lymphoepithelioma-like carcinoma. Phase 3 clinical trials for patients with SCLC and NPC have already been initiated. ClinicalTrials.gov identifiers: NCT05434234 and NCT06057922 . In a large-scale, international, multicenter, phase 1/1b trial, treatment of patients with advanced solid tumors with the B7H3-targeting antibody–drug conjugate YL201 was safe and showed preliminary clinical efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-025-03600-2

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study flowchart and patient disposition. Q3W, 1 dose every 3 weeks per cycle.
Fig. 1 Study flowchart and patient disposition. Q3W, 1 dose every 3 weeks per cycle.CC BY-NC-ND · PubMed Central
Fig. 2 Waterfall plot of tumor response from baseline and swimming plot. a,c,e,g, The waterfall plot depicts the best objective responses concerning the tumor size in all patients (a), ES-SCLC (c), NPC (e) and LELC (g). b,d,f,h, Swimmer plots depict responses to treatment and the duration of treatment in all patients (b), ES-SCLC (d), NPC (f) and LELC (h).
Fig. 2 Waterfall plot of tumor response from baseline and swimming plot. a,c,e,g, The waterfall plot depicts the best objective responses concerning the tumor size in all patients (a), ES-SCLC (c), NPC (e) and LELC (g). b,d,f,h, Swimmer plots depict responses to treatment and the duration of treatment in all patients (b), ES-SCLC (d), NPC (f) and LELC (h).CC BY-NC-ND · PubMed Central
Fig. 3 Expression of B7-H3 in different tumor types and the relationship between B7-H3 expression and response. a, Expression of B7H3 in different tumor types. b–f, The relationship between B7-H3 expression and response in all patients (b), ES-SCLC (c), NPC (d), ESCC (e) and LELC (f). The median, quartile, and maximum and minimum values are shown. Comparisons were performed using Kruskal–Wallis one-way ANOVA tests. NE, not evaluated; cBOR, confirmed best overall response. Source data
Fig. 3 Expression of B7-H3 in different tumor types and the relationship between B7-H3 expression and response. a, Expression of B7H3 in different tumor types. b–f, The relationship between B7-H3 expression and response in all patients (b), ES-SCLC (c), NPC (d), ESCC (e) and LELC (f). The median, quartile, and maximum and minimum values are shown. Comparisons were performed using Kruskal–Wallis one-way ANOVA tests. NE, not evaluated; cBOR, confirmed best overall response. Source dataCC BY-NC-ND · PubMed Central
Extended Data Fig. 1 Overview of the dose-escalation and dose-expansion studies. DLT, dose-limiting toxicity; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; Q3W, once every 3 weeks.
Extended Data Fig. 1 Overview of the dose-escalation and dose-expansion studies. DLT, dose-limiting toxicity; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; Q3W, once every 3 weeks.CC BY-NC-ND · PubMed Central
Extended Data Fig. 2 Waterfall plot of tumor response from baseline and swimmers plot in lung adenocarcinoma, lung squamous cell carcinoma, esophageal squamous cell carcinoma, and other tumor patients. The waterfall plot depicts the best objective responses concerning the tumor size in lung adenocarcinoma (a), lung squamous cell carcinoma (c), ESCC(e) and other tumors (g). Corresponding swimmer plots depict the treatment duration and response patterns for lung adenocarcinoma (b), lung squamous cell carcinoma (d), ESCC (f), and other tumors (h). BOR, the best of response; PR, partial response; SD, stable disease; PD, progressive disease. ESCC, esophageal squamous cell carcinoma.
Extended Data Fig. 2 Waterfall plot of tumor response from baseline and swimmers plot in lung adenocarcinoma, lung squamous cell carcinoma, esophageal squamous cell carcinoma, and other tumor patients. The waterfall plot depicts the best objective responses concerning the tumor size in lung adenocarcinoma (a), lung squamous cell carcinoma (c), ESCC(e) and other tumors (g). Corresponding swimmer plots depict the treatment duration and response patterns for lung adenocarcinoma (b), lung squamous cell carcinoma (d), ESCC (f), and other tumors (h). BOR, the best of response; PR, partial response; SD, stable disease; PD, progressive disease. ESCC, esophageal squamous cell carcinoma.CC BY-NC-ND · PubMed Central
Extended Data Fig. 3 Waterfall plot of best response of intracranial target lesions in patients with evaluable brain metastases at baseline. ES-SCLC, extensive-stage small cell lung cancer; NSCLC, non-small cell lung cancer; adeno, adenocarcinoma; ESCC, esophageal squamous cell carcinoma.
Extended Data Fig. 3 Waterfall plot of best response of intracranial target lesions in patients with evaluable brain metastases at baseline. ES-SCLC, extensive-stage small cell lung cancer; NSCLC, non-small cell lung cancer; adeno, adenocarcinoma; ESCC, esophageal squamous cell carcinoma.CC BY-NC-ND · PubMed Central
Extended Data Fig. 4 Typical radiographic images of patients who achieved partial responses. (a) A 51-year-old small cell lung cancer patient achieved partial responses after two and four cycles of YL201 treatment (red arrow showing target lesion in the lymph node metastasis). (b) A 49-year-old nasopharyngeal carcinoma patient achieved partial responses after two and four cycles treatment (red arrow showing target lesion in the liver metastasis). (c) A 62-year-old lung lymphoepithelioma-like carcinoma patient achieved partial responses after four and six cycles treatment (red arrow showing target lesion in the lung).
Extended Data Fig. 4 Typical radiographic images of patients who achieved partial responses. (a) A 51-year-old small cell lung cancer patient achieved partial responses after two and four cycles of YL201 treatment (red arrow showing target lesion in the lymph node metastasis). (b) A 49-year-old nasopharyngeal carcinoma patient achieved partial responses after two and four cycles treatment (red arrow showing target lesion in the liver metastasis). (c) A 62-year-old lung lymphoepithelioma-like carcinoma patient achieved partial responses after four and six cycles treatment (red arrow showing target lesion in the lung).CC BY-NC-ND · PubMed Central
Extended Data Fig. 5 Single dose concentration-time plot concentration over time at different dosage regimens. Single dose concentration-time plot concentration different dosage regimens of YL201-ADC, YL201-TAB and YL0010014 in the first cycle in the dose-escalation phase. Data are represented as mean and the standard deviation. ADC, antibody-drug conjugate; TAB, total antibody.
Extended Data Fig. 5 Single dose concentration-time plot concentration over time at different dosage regimens. Single dose concentration-time plot concentration different dosage regimens of YL201-ADC, YL201-TAB and YL0010014 in the first cycle in the dose-escalation phase. Data are represented as mean and the standard deviation. ADC, antibody-drug conjugate; TAB, total antibody.CC BY-NC-ND · PubMed Central
Extended Data Fig. 6 The correlation analysis of tumor B7-H3 Expression and objective response across different tumor types. According to the cutoff of the H-score of 100, the patients were divided into two groups: low expression of B7H3 and high expression of B7H3, and the difference of objective response rate between two groups in ES-SCLC (a), NPC (b), ESCC (c), ESCC (d), and NSCLC adenocarcinoma (e) was compared. Statistical significance was determined using Chi-squared test. ES-SCLC, extensive-stage small cell lung cancer; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; LELC, lymphoepithelioma-like carcinoma; ESCC, esophageal squamous cell carcinoma; NE, not evaluated; PD, progressive disease; SD, stable disease; PR, partial response. Source data
Extended Data Fig. 6 The correlation analysis of tumor B7-H3 Expression and objective response across different tumor types. According to the cutoff of the H-score of 100, the patients were divided into two groups: low expression of B7H3 and high expression of B7H3, and the difference of objective response rate between two groups in ES-SCLC (a), NPC (b), ESCC (c), ESCC (d), and NSCLC adenocarcinoma (e) was compared. Statistical significance was determined using Chi-squared test. ES-SCLC, extensive-stage small cell lung cancer; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; LELC, lymphoepithelioma-like carcinoma; ESCC, esophageal squamous cell carcinoma; NE, not evaluated; PD, progressive disease; SD, stable disease; PR, partial response. Source dataCC BY-NC-ND · PubMed Central
Extended Data Fig. 7 Scatter plot of pre-treatment soluble B7-H3 concentration by objective responses across different tumor types. Concentration of soluble B7-H3 in different tumor types (a). The relationship between the soluble B7-H3 concentration and the response in all patients (b), ES-SCLC (c), NPC (d), ESCC (e), lung adenocarcinoma (f), lung squamous cell carcinoma (g) and LELC (h). The median, quartile, maximum and minimum values are shown. Comparisons were performed using Kruskal-Wallis one-way ANOVA tests followed by Dunn’s correction for multiple comparisons. ES-SCLC, extensive-stage small cell lung cancer; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; lung lymphoepithelioma-like carcinoma. sB7H3, soluble B7-H3; ES-SCLC, extensive-stage small cell lung cancer; ESCC, esophageal squamous cell carcinoma; ade, adenocarcinoma; squ-NSCLC, lung squamous cell carcinoma; LELC, lymphoepithelioma-like carcinoma. Source data
Extended Data Fig. 7 Scatter plot of pre-treatment soluble B7-H3 concentration by objective responses across different tumor types. Concentration of soluble B7-H3 in different tumor types (a). The relationship between the soluble B7-H3 concentration and the response in all patients (b), ES-SCLC (c), NPC (d), ESCC (e), lung adenocarcinoma (f), lung squamous cell carcinoma (g) and LELC (h). The median, quartile, maximum and minimum values are shown. Comparisons were performed using Kruskal-Wallis one-way ANOVA tests followed by Dunn’s correction for multiple comparisons. ES-SCLC, extensive-stage small cell lung cancer; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; lung lymphoepithelioma-like carcinoma. sB7H3, soluble B7-H3; ES-SCLC, extensive-stage small cell lung cancer; ESCC, esophageal squamous cell carcinoma; ade, adenocarcinoma; squ-NSCLC, lung squamous cell carcinoma; LELC, lymphoepithelioma-like carcinoma. Source dataCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 122

Metadata

Authors
Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., Liu, J., Liu, Z., Zhuang, W., Rosen, S., Qu, S., Li, B., Li, M., Zhao, Y., Yang, S., Ji, Y., Sommerhalder, D., Luo, S., Yang, K., Li, J., Lv, D., Zhang, P., Zhao, Y., Hong, S., Zhang, Y., Zhao, S., Chin, S., Zhang, X., Lian, W., Cai, J., Xue, T., Zhang, L., & Zhao, H.
Affiliations
  • Sun Yat-sen University Cancer Center (CN)
  • Shandong Tumor Hospital (CN)
  • Zhejiang Cancer Hospital (CN)
  • The University of Texas MD Anderson Cancer Center (US)
  • Hunan Cancer Hospital (CN)
  • First Affiliated Hospital Zhejiang University (CN)
  • Fujian Provincial Cancer Hospital (CN)
  • Hematology Oncology Associates (US)
  • Guangxi Medical University (CN)
  • Guilin Medical University (CN)
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Henan Cancer Hospital (CN)
  • First Affiliated Hospital of Xinxiang Medical University (CN)
  • Wuhan Union Hospital (CN)
  • Jiangxi Provincial Cancer Hospital (CN)
  • Sichuan Cancer Hospital (CN)
  • MediLink Therapeutics (Suzhou) Co., Ltd. (China) (CN)
Corresponding author
  • Xue, Tongtong
  • Zhang, Li
  • Zhao, Hongyun
Venue
Nature Medicine
Published
2025-03-13
Volume
31
Issue
6
Pages
1949-1957
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4408413512
Cited by
122
References
34
Citations by year
2026: 92 · 2025: 30
FWCI
70.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (82473346, 82272789)
  • Guangzhou Science &Technology Project
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
antibody-drug conjugates, B7-H3, topoisomerase I inhibitor, protease-cleavable linker, extensive-stage small cell lung cancer, nasopharyngeal carcinoma, lymphoepithelioma-like carcinoma, non-small cell lung cancer, esophageal squamous cell carcinoma, maximum tolerated dose, objective response rate, refractory solid tumors
MeSH terms
Nasopharyngeal Carcinoma, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasms, Immunoconjugates, Maximum Tolerated Dose, B7 Antigens

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial. https://app.cochat.ai/papers/10.1038/s41591-025-03600-2
The paper
Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., Liu, J., Liu, Z., Zhuang, W., Rosen, S., Qu, S., Li, B., Li, M., Zhao, Y., Yang, S., . . . Zhao, H. (2025). A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial. Nature Medicine. https://doi.org/10.1038/s41591-025-03600-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.